Short-term efficacy of cetuximab-contained regimen on patients with advanced gastric and esophageal cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 217-219, 2010.
Artigo
em Chinês
| WPRIM
| ID: wpr-389965
ABSTRACT
Few studies of cetuximab on patients with gastric and esophageal cancer were available now.The disease control rate was 72.7%~92%,OS was 9.5~16.6months,PFS/was 6.2~11 months among first-line setting with cetuximab-contained regimens.And cetuximab shown in second-line regimen setting overcome the resistance of irinotecan and docetaxel.The pCR was 13%~65% when cetuximab was used as induction treatment combined with concurrent chemoradiation.18F-FDG-PET was a potential method to predictthe efficacy of cetuximab-contained regimens,however,status of Kras gene had no predictive value.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS